Cargando…
Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment
Adult T-cell leukaemia/lymphoma (ATLL) is an aggressive malignancy of mature activated T cells caused by human T-cell lymphotropic virus type I (HTLV-1). Prognosis is severe because of intrinsic chemoresistance and severe immuosuppression. Four different subtypes are described with different outcome...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504218/ https://www.ncbi.nlm.nih.gov/pubmed/23213552 http://dx.doi.org/10.1155/2012/932175 |
_version_ | 1782250590693228544 |
---|---|
author | Marçais, Ambroise Suarez, Felipe Sibon, David Bazarbachi, Ali Hermine, Olivier |
author_facet | Marçais, Ambroise Suarez, Felipe Sibon, David Bazarbachi, Ali Hermine, Olivier |
author_sort | Marçais, Ambroise |
collection | PubMed |
description | Adult T-cell leukaemia/lymphoma (ATLL) is an aggressive malignancy of mature activated T cells caused by human T-cell lymphotropic virus type I (HTLV-1). Prognosis is severe because of intrinsic chemoresistance and severe immuosuppression. Four different subtypes are described with different outcomes, and treatment strategies vary according to the different clinical courses. Japanese trials show that combinations of chemotherapy can increase the response rates especially in the lymphoma subtype. However, patients have a high rate of relapse and the outcome remains extremely poor. Recently, a worldwide meta-analysis demonstrated that the combination of Zidovudine and Interferon-alpha (IFN) is effective in the leukemic subtypes (smoldering, chronic, and acute) and influences favorably the course of the disease. In order to prevent relapse, clinical trials testing new drugs such as monoclonal antibodies or combinations such as arsenic/IFN are needed. Finally, allogeneic stem cell transplantation is a feasible option but bears a very high rate of complications. |
format | Online Article Text |
id | pubmed-3504218 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-35042182012-12-04 Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment Marçais, Ambroise Suarez, Felipe Sibon, David Bazarbachi, Ali Hermine, Olivier Leuk Res Treatment Review Article Adult T-cell leukaemia/lymphoma (ATLL) is an aggressive malignancy of mature activated T cells caused by human T-cell lymphotropic virus type I (HTLV-1). Prognosis is severe because of intrinsic chemoresistance and severe immuosuppression. Four different subtypes are described with different outcomes, and treatment strategies vary according to the different clinical courses. Japanese trials show that combinations of chemotherapy can increase the response rates especially in the lymphoma subtype. However, patients have a high rate of relapse and the outcome remains extremely poor. Recently, a worldwide meta-analysis demonstrated that the combination of Zidovudine and Interferon-alpha (IFN) is effective in the leukemic subtypes (smoldering, chronic, and acute) and influences favorably the course of the disease. In order to prevent relapse, clinical trials testing new drugs such as monoclonal antibodies or combinations such as arsenic/IFN are needed. Finally, allogeneic stem cell transplantation is a feasible option but bears a very high rate of complications. Hindawi Publishing Corporation 2012 2012-02-14 /pmc/articles/PMC3504218/ /pubmed/23213552 http://dx.doi.org/10.1155/2012/932175 Text en Copyright © 2012 Ambroise Marçais et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Marçais, Ambroise Suarez, Felipe Sibon, David Bazarbachi, Ali Hermine, Olivier Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment |
title | Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment |
title_full | Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment |
title_fullStr | Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment |
title_full_unstemmed | Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment |
title_short | Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment |
title_sort | clinical trials of adult t-cell leukaemia/lymphoma treatment |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504218/ https://www.ncbi.nlm.nih.gov/pubmed/23213552 http://dx.doi.org/10.1155/2012/932175 |
work_keys_str_mv | AT marcaisambroise clinicaltrialsofadulttcellleukaemialymphomatreatment AT suarezfelipe clinicaltrialsofadulttcellleukaemialymphomatreatment AT sibondavid clinicaltrialsofadulttcellleukaemialymphomatreatment AT bazarbachiali clinicaltrialsofadulttcellleukaemialymphomatreatment AT hermineolivier clinicaltrialsofadulttcellleukaemialymphomatreatment |